Trial Profile

The efficacy and safety of Eftilagimod Alpha Treatment by immune modulation in COVID-19 disease (EAT COVID trial)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 19 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eftilagimod alpha (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use
Acronyms EAT COVID

Most Recent Events

17 Sep 2022 Status changed from recruiting to discontinued.
27 Jan 2021 According to an Immutep Limited media release, an independent Data and Safety Monitoring Board (DSMB) has completed a safety run-in data review of the first six patients from this study. Following this data review, the DSMB recommended that the study advance with enrolment for the randomised portion of the study.
21 Jan 2021 According to an Immutep media release, initial results from the safety run in of the trial are expected to be reported in early 2021 with initial interim efficacy results in 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com